title: Increased lead excretion correlates with desoxypyridinoline crosslinks in hyperthyroid patients.
abstract: Lead is a widespread toxic metal that accumulates predominantly in human bone. Altered bone metabolism in hyperthyroidism is characterized mainly by bone resorption. Thus, we speculated that lead excretion could be increased in hyperthyroid patients. In 12 hyperthyroid patients (43.3 +/- 16.1 years) who were not previously occupationally exposed to lead, lead concentrations in blood (PbB), spot urine samples corrected by urine creatinine (PbUs), and in 24-hour urine samples (PbU24) were determined in the hyperthyroid state and after euthyroidism had been induced by therapy. Serum osteocalcin (OC) and desoxypyridinoline crosslinks (Pyr) served as specific markers for bone metabolism. After induction of euthyroidism (duration of antithyroid therapy: mean 17.3 +/- 6.9 weeks) PbB was reduced (3.7 +/- 2.6 vs. 5.7 +/- 4.7 microg/dL, p = 0.041) as was PbUs (0.39 +/-0.27 vs. 0.61 +/- 0.32 microg/mg Cr, p = 0.005). A fourfold decrease of PbU24 was associated with a 3.3-fold decrease of Pyr, and moreover there was a significant correlation between Pyr and PbUs (r = 0.58, p = 0.047). Concentration of total triiodothyronine correlated with Pyr (r = 0.66, p = 0.018), but not with PbB or PbUs. OC showed only a tendency to be increased before antithyroid medication, and did not correlate with either thyroid hormone or Pyr. Our results indicate that in hyperthyroid patients, even when not previously exposed to lead, lead excretion is increased due to bone resorption.
authors.affiliation: Universitätsklinik für Innere Medizin IV, Klinische Abteilung f. Arbeitsmedizin, Wien (Vienna), Austria. wolf.osterode@akh-wien.ac.at
authors.forename: W
authors.initials: W
authors.lastname: Osterode
authors.forename: G
authors.initials: G
authors.lastname: Reining
authors.forename: G
authors.initials: G
authors.lastname: Männer
authors.forename: J
authors.initials: J
authors.lastname: Jäger
authors.forename: H
authors.initials: H
authors.lastname: Vierhapper
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D002940:Circadian Rhythm; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy / Q000652:urine*; D007854:Lead / Q000097:blood / Q000652:urine*; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D011725:Pyridines / Q000097:blood / Q000737:chemistry; D012016:Reference Values
chemical_list: D013956:Antithyroid Agents; D011725:Pyridines; D015675:Osteocalcin; D007854:Lead; D008713:Methimazole; D003404:Creatinine